XML 46 R35.htm IDEA: XBRL DOCUMENT
v3.26.1

Segments of Business (Tables) | 3 Months Ended
--- | ---
Jun. 30, 2026
Segment Reporting [Abstract] |
Schedule of Segment Information | Financial information relating to the Company’s reportable segments and reconciliations to the consolidated totals was as follows:
| Three Months Ended June 30, |  |
(In millions) | 2026 |  | 2025 |  |  |  |
Segment revenues (1) |  |  |  |  |  |  |
North American Pharmaceutical | $ | 86,773 |  |  | $ | 82,729 |  |  |  |  |
Oncology & Multispecialty | 14,222 |  |  | 10,658 |  |  |  |  |
Prescription Technology Solutions | 1,566 |  |  | 1,434 |  |  |  |  |
Medical-Surgical Solutions | 2,819 |  |  | 2,701 |  |  |  |  |
Other | — |  |  | 305 |  |  |  |  |
Total revenues | $ | 105,380 |  |  | $ | 97,827 |  |  |  |  |
Other segment expense, net (2) |  |  |  |  |  |  |
North American Pharmaceutical (3) | $ | 85,870 |  |  | $ | 82,135 |  |  |  |  |
Oncology & Multispecialty | 13,897 |  |  | 10,446 |  |  |  |  |
Prescription Technology Solutions (4) | 1,340 |  |  | 1,181 |  |  |  |  |
Medical-Surgical Solutions (5) | 2,697 |  |  | 2,480 |  |  |  |  |
Other | — |  |  | 292 |  |  |  |  |
Total other segment expense, net | $ | 103,804 |  |  | $ | 96,534 |  |  |  |  |
Segment operating profit |  |  |  |  |  |  |
North American Pharmaceutical | $ | 903 |  |  | $ | 594 |  |  |  |  |
Oncology & Multispecialty | 325 |  |  | 212 |  |  |  |  |
Prescription Technology Solutions | 226 |  |  | 253 |  |  |  |  |
Medical-Surgical Solutions | 122 |  |  | 221 |  |  |  |  |
Other | — |  |  | 13 |  |  |  |  |
Subtotal | 1,576 |  |  | 1,293 |  |  |  |  |
Corporate expenses, net (6) | (191) |  |  | (193) |  |  |  |  |
Interest expense | (77) |  |  | (49) |  |  |  |  |
Income before income taxes | $ | 1,308 |  |  | $ | 1,051 |  |  |  |  |
Segment depreciation and amortization (7) |  |  |  |  |  |  |
North American Pharmaceutical | $ | 39 |  |  | $ | 32 |  |  |  |  |
Oncology & Multispecialty | 66 |  |  | 42 |  |  |  |  |
Prescription Technology Solutions | 19 |  |  | 21 |  |  |  |  |
Medical-Surgical Solutions | 26 |  |  | 22 |  |  |  |  |
Other | — |  |  | 3 |  |  |  |  |
Corporate | 45 |  |  | 37 |  |  |  |  |
Total segment depreciation and amortization | $ | 195 |  |  | $ | 157 |  |  |  |  |
Segment expenditures for long-lived assets (8) |  |  |  |  |  |  |
North American Pharmaceutical | $ | 64 |  |  | $ | 61 |  |  |  |  |
Oncology & Multispecialty | 18 |  |  | 24 |  |  |  |  |
Prescription Technology Solutions | — |  |  | 1 |  |  |  |  |
Medical-Surgical Solutions | 27 |  |  | 25 |  |  |  |  |
Other | — |  |  | 1 |  |  |  |  |
Corporate | 43 |  |  | 77 |  |  |  |  |
Total segment expenditures for long-lived assets | $ | 152 |  |  | $ | 189 |  |  |  |  |
(1)Revenues from services on a disaggregated basis represent less than 1% of the North American Pharmaceutical segment’s total revenues, approximately 7% of the Oncology & Multispecialty segment’s total revenues, approximately 39% of the Prescription Technology Solutions segment’s total revenues, and less than 1% of the Medical-Surgical Solutions segment’s total revenues. The Company’s Norwegian operations were included in Other. (2)Other segment expense, net includes cost of sales, total operating expenses, as well as other income, net, for the Company’s reportable segments. (3)The Company’s North American Pharmaceutical other segment expense, net includes the following: •related to the bankruptcy of the Company’s customer Rite Aid Corporation (including certain of its subsidiaries, “Rite Aid”), the Company recorded a provision for bad debts of $189 million during the three months ended June 30, 2025. This was recorded within “Selling, distribution, general, and administrative expenses” in the Company’s Condensed Consolidated Statements of Operations. (4)The Company’s Prescription Technology Solutions other segment expense, net includes the following: •restructuring charges of $61 million for the three months ended June 30, 2026 for restructuring initiatives as discussed in Financial Note 3, “Restructuring, Impairment, and Related Charges, Net.” (5)The Company’s Medical-Surgical Solutions other segment expense, net includes the following: •charges of $45 million for the three months ended June 30, 2026 related to the planned separation of the Medical-Surgical Solutions business. (6)Corporate expenses, net include the following: •restructuring charges of $50 million and $29 million for the three months ended June 30, 2026 and 2025, respectively, for restructuring initiatives as discussed in Financial Note 3, “Restructuring, Impairment, and Related Charges, Net;” •a credit of $34 million for the three months ended June 30, 2026 related to the estimated liability for opioid related claims, as discussed in Financial Note 11, “Commitments and Contingent Liabilities;” and •charges of $23 million for the three months ended June 30, 2026 related to the planned separation of the Medical-Surgical Solutions business. (7)Amounts primarily consist of amortization of acquired intangible assets purchased in connection with business acquisitions and capitalized software for internal use as well as depreciation and amortization of property, plant, and equipment, net. (8)Long-lived assets consist of property, plant, and equipment, net and capitalized software.
Schedule of Long-lived Assets By Geographic Areas | Long-lived assets by geographic areas were as follows:
(In millions) | June 30, 2026 |  | March 31, 2026
Long-lived assets |  |  |
United States | $ | 3,185 |  |  | $ | 3,177 |
Foreign | 244 |  |  | 255 |
Total long-lived assets | $ | 3,429 |  |  | $ | 3,432 |

X
- Definition Tabular disclosure of reconciliation of asset by reportable segment to consolidated asset. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 + Details
Name: | us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of segment reporting. Includes, but is not limited to, reconciliation of reportable segment amount to corresponding consolidated total. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 34 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-34 Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 26C -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 26B -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 26A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26A Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25 Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-15 + Details
Name: | us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration